🔴 Niagen Bioscience is trading 15.9% down today after Q2 revenue miss and rising marketing expenses

Niagen Bioscience is trading 15.9% down at $3.12 after its Q2 revenue missed analyst estimates and marketing costs surged.

• Net sales reached $29.8 million, missing analyst projections, while earnings per share of $0.01 only matched expectations amid a year-over-year revenue decline.
• Sales and marketing expenses spiked to 34% of net sales, impacting net income and raising concerns regarding near-term profitability despite solid direct-to-consumer (DTC) growth and maintained full-year guidance.